Log In Sign up
The largest database of trusted experimental protocols
> Procedures > Diagnostic Procedure > Computed Tomography Angiography

Computed Tomography Angiography

Computed Tomography Angiography (CTA) is a non-invasive imaging technique that uses X-rays and computer processing to generate detailed, three-dimensional images of blood vessels throughout the body.
CTA is commonly used to evaluate cardiovascular conditions, such as coronary artery disease, aortic aneurysms, and peripheral vascular disease.
The procedure involves injecting a contrast dye into the bloodstream, which allows the blood vessels to be clearly visualized on the CT scans.
CTA provides high-resolution images that can help clinicians diagnose and monitor vascular disorders, as well as plan appropriate treatment strategies.
This advanced imaging modality has become an increasingly important tool in modern cardiovascular care.

Most cited protocols related to «Computed Tomography Angiography»

1
Late-Window Endovascular Stroke Therapy Eligibility
The trial was performed at 38 centers in the United States. Neurointerventionalists were preapproved to participate on the basis of training and experience. (For approval requirements, see the Supplementary Appendix, available with the full text of this article at NEJM.org.) Enrolled patients or their surrogates provided written informed consent. Patients were enrolled if they met clinical and imaging eligibility requirements and could undergo initiation of endovascular therapy between 6 and 16 hours after the time that they had last been known to be well, including if they had awakened from sleep with symptoms of a stroke. Perfusion imaging had to be performed at the trial-site hospital in which endovascular therapy was planned.
Patients were eligible if they had an initial infarct volume (ischemic core) of less than 70 ml, a ratio of volume of ischemic tissue to initial infarct volume of 1.8 or more, and an absolute volume of potentially reversible ischemia (penumbra) of 15 ml or more. Estimates of the volume of the ischemic core and penumbral regions from CT perfusion or MRI diffusion and perfusion scans were calculated with the use of RAPID software (iSchemaView), an automated image postprocessing system. The size of the penumbra was estimated from the volume of tissue for which there was delayed arrival of an injected tracer agent (time to maximum of the residue function [Tmax]) exceeding 6 seconds.8 (link) (An example is given in Fig. 1.) Patients were required to have an occlusion of the cervical or intracranial internal carotid artery or the proximal middle cerebral artery on CT angiography (CTA) or magnetic resonance angiography (MRA). Detailed inclusion and exclusion criteria for the trial are provided in the Supplementary Appendix.
Albers G.W., Marks M.P., Kemp S., Christensen S., Tsai J.P., Ortega-Gutierrez S., McTaggart R.A., Torbey M.T., Kim-Tenser M., Leslie-Mazwi T., Sarraj A., Kasner S.E., Ansari S.A., Yeatts S.D., Hamilton S., Mlynash M., Heit J.J., Zaharchuk G., Kim S., Carrozzella J., Palesch Y.Y., Demchuk A.M., Bammer R., Lavori P.W., Broderick J.P, & Lansberg M.G. (2018). Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging. The New England journal of medicine, 378(8), 708-718.
Publication 2018
Cerebrovascular Accident Computed Tomography Angiography Dental Occlusion Diffusion Magnetic Resonance Imaging Eligibility Determination Infarction Internal Carotid Arteries Ischemia Magnetic Resonance Angiography Middle Cerebral Artery Neck Neoplasm Metastasis Patients Perfusion Radionuclide Imaging Sleep Therapeutics Tissues
2
Validating PheWAS Phenotype Associations
All distinct ICD9 billing codes from each of the individuals' records were captured and translated into corresponding case groupings. For our purposes, a ‘case’ is a record that has a single, valid ICD9 code that maps to PheWAS case group. Other individuals were marked as ‘controls’ for a given case if they did not have any ICD9 codes belonging to the exclusion code grouping corresponding for that case. The PheWAS algorithm, then calculates case and control genotype distributions and calculates the χ2 distribution, associated allelic P-value and allelic odds ratio (OR). For those χ2 distributions in which observed cell counts fell below five, Fisher's exact test was used to calculate the P-value using the R statistical package (http://www.r-project.org/). Since many phenotypes, even after ICD9 code groupings, occur rarely, we selected only those that occurred in a minimum of 25 cases (0.42% of genotyped patients) as a threshold of clinical interest.
After the initial study, we conducted a failure analysis on the previously associated phenotypes that did not replicate using the PheWAS method. To investigate these further, we performed a physician chart review on all individuals with SLE and CAS by PheWAS code groups and analyzed the electrocardiograms of all patients with ICD9 codes indicative of AF. Our gold-standard definition of SLE required that a treating physician document an SLE diagnosis and immunosuppressive treatment via a clinical note or problem list. True positive cases of CAS required presence of carotid duplex sonography, traditional angiography, computed tomography angiography or magnetic resonance angiography demonstrating hemodynamically significant stenosis of the common or internal carotid artery. We assessed AF cases by processing all electrocardiograms using a previously validated natural language processing algorithm (Denny et al., 2005 (link)).
Denny J.C., Ritchie M.D., Basford M.A., Pulley J.M., Bastarache L., Brown-Gentry K., Wang D., Masys D.R., Roden D.M, & Crawford D.C. (2010). PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene–disease associations. Bioinformatics, 26(9), 1205-1210.
Publication 2010
Alleles Angiography Computed Tomography Angiography Diagnosis Electrocardiogram Gold Immunosuppressive Agents Internal Carotid Arteries Magnetic Resonance Angiography Microtubule-Associated Proteins Patients Phenotype Physicians Stenosis Ultrasonography, Carotid Arteries
3
MR CLEAN Registry Endovascular Stroke Therapy
Enrolment in the MR CLEAN Registry started directly after the final randomisation in the MR CLEAN trial on 16 March 2014. From 16 March 2014 to 31 December 2014 this was done retrospectively. From January 2015 onwards, enrolment was prospective. Sixteen centres participated in the MR CLEAN trial and are considered “MR CLEAN centres.” Two non-MR CLEAN centres started performing endovascular treatment later on and added patients to the MR CLEAN Registry, but these patients are not included in this analysis. The study data for patients undergoing endovascular treatment up to 15 June 2016 in the 16 MR CLEAN centres were completed and analysed and are reported here.
All patients undergoing endovascular treatment (defined as entry into the angiography suite and receiving arterial puncture) for acute ischaemic stroke in the anterior and posterior circulation have been registered in the MR CLEAN Registry. To adequately compare results with the MR CLEAN trial, in the current analysis we included those patients who adhered to the following criteria: arterial puncture within 6.5 hours of symptom onset, age 18 years and older, treatment in a centre that participated in the MR CLEAN trial, and proximal intracranial vessel occlusion in the anterior circulation (internal carotid artery (ICA), internal carotid artery terminus (ICA-T), middle (M1/M2) cerebral artery, or anterior (A1/A2) cerebral artery), shown by computed tomography angiography, magnetic resonance angiography, or digital subtraction angiography. No upper age limit, minimum Alberta Stroke Program Early Computed Tomography Score (ASPECTS), or collateral grade were imposed on treating doctors, nor was an extracranial occlusion by atherosclerosis or dissection an exclusion criterion.
Jansen I.G., Mulder M.J, & Goldhoorn R.J. (2018). Endovascular treatment for acute ischaemic stroke in routine clinical practice: prospective, observational cohort study (MR CLEAN Registry). The BMJ, 360, k949.
Publication 2018
Acute Ischemic Stroke Angiography Angiography, Digital Subtraction Angle Class III Arteries Atherosclerosis Blood Vessel Cerebral Arteries Cerebrovascular Accident Computed Tomography Angiography Dental Occlusion Dissection Internal Carotid Arteries Magnetic Resonance Angiography Patients Physicians Punctures X-Ray Computed Tomography
4
Eligibility Criteria for Carotid Revascularization
Patients were considered to be symptomatic if they had had a transient ischemic attack, amaurosis fugax, or minor nondisabling stroke involving the study carotid artery within 180 days before randomization. Eligibility criteria were stenosis of 50% or more on angiography, 70% or more on ultrasonography, or 70% or more on computed tomographic angiography or magnetic resonance angiography if the stenosis on ultrasonography was 50 to 69%. Eligibility was extended in 2005 to include asymptomatic patients, for whom the criteria were stenosis of 60% or more on angiography, 70% or more on ultrasonography, or 80% or more on computed tomographic angiography or magnetic resonance angiography if the stenosis on ultrasonography was 50 to 69%. Patients were excluded if they had had a previous stroke that was sufficiently severe to confound the assessment of end points or if they had chronic atrial fibrillation, paroxysmal atrial fibrillation that had occurred within the preceding 6 months or that necessitated anticoagulation therapy, myocardial infarction within the previous 30 days, or unstable angina. Additional eligibility criteria were clinical and anatomical suitability, before randomization, for management by means of either of the study revascularization techniques. The full eligibility criteria have been published elsewhere.10 (link)
Brott T.G., Hobson RW I.I., Howard G., Roubin G.S., Clark W.M., Brooks W., Mackey A., Hill M.D., Leimgruber P.P., Sheffet A.J., Howard V.J., Moore W.S., Voeks J.H., Hopkins L.N., Cutlip D.E., Cohen D.J., Popma J.J., Ferguson R.D., Cohen S.N., Blackshear J.L., Silver F.L., Mohr J.P., Lal B.K, & Meschia J.F. (2010). Stenting versus Endarterectomy for Treatment of Carotid-Artery Stenosis. The New England journal of medicine, 363(1), 11-23.
Publication 2010
Amaurosis Fugax Angina, Unstable Angiography Atrial Fibrillation Carotid Arteries Cerebrovascular Accident Computed Tomography Angiography Eligibility Determination Fibrillation, Paroxysmal Atrial Magnetic Resonance Angiography Myocardial Infarction Patients Stenosis Therapeutics Transient Ischemic Attack Ultrasonography
5
Diagnostic Accuracy of 64-Slice CT Angiography
The “Coronary Evaluation Using Multidetector Spiral Computed Tomography Angiography using 64 Detectors” or “CORE-64” study was designed to evaluate the diagnostic accuracy of multislice spiral CT angiography using 64 detector rows for identifying coronary artery stenosis in patients with suspected or known significant coronary artery disease. The study was designed as a prospective, multi-centre (nine centres), international (seven countries) study examining the diagnostic accuracy of 64-slice CT in comparison with CCA. The primary hypothesis of the study was that 64-slice CT coronary angiography will be able to detect significant coronary artery disease in a patient with acceptable diagnostic accuracy as compared to CCA. Significant CAD is defined as ≥50% stenosis as determined by coronary angiography (QCA) of CCA. The primary diagnostic parameters were per-patient sensitivity and specificity compared with CCA. These were analysed using both point estimates and continuous measurements (using area under the receiver-operating characteristics curve) expressed with 95% confidence intervals for the corresponding true values to indicate the precision of the estimates. We also compared the diagnostic performance of CCA with that of MSCT for anatomy-based prediction of subsequent clinically driven revascularisation on a per-patient and per-vessel level. Other secondary objectives include the evaluation of diagnostic accuracy based on a per-vessel and per-segment unit of analysis, and defining significant stenosis at both ≥50% and ≥70% thresholds, with QCA as the reference standard.
Miller J.M., Dewey M., Vavere A.L., Rochitte C.E., Niinuma H., Arbab-Zadeh A., Paul N., Hoe J., de Roos A., Yoshioka K., Lemos P.A., Bush D.E., Lardo A.C., Texter J., Brinker J., Cox C., Clouse M.E, & Lima J.A. (2008). Coronary CT angiography using 64 detector rows: methods and design of the multi-centre trial CORE-64. European Radiology, 19(4), 816-828.
Publication 2008
Blood Vessel Computed Tomography Angiography Coronary Angiography Coronary Artery Disease Coronary Stenosis Diagnosis Heart Patients Stenosis

Most recents protocols related to «Computed Tomography Angiography»

1
Carotid Stenosis and Ischemic Stroke Evaluation
In this dataset, 282 patients are included (mean age 69.8 ± 9.4; 250 males, 66 females) from July 2020 to September 2022, who had internal carotid artery stenosis of > 50% diagnosed by computed tomograph (CT) angiography or magnetic resonance (MR) angiography. Of all the patients, 151 have experienced ischemic stroke before they were diagnosed of carotid stenosis, the remaining 131 were asymptomatic with no neurological abnormalities. The common clinical symptoms of ischemic stroke include weakness or numbness of the face, arm or leg, trouble speaking and understanding, and monocular blindness. The study was approved by the ethics committee of our institution and informed consent was obtained from all patients.
The exclusion criteria were as follows:
All the patients underwent brain MR examination using a 1.5 or 3.0 Tesla (T) MR scanner within 1 week of their carotid artery examination. The MRI protocol included T1WI, T2WI, FLAIR, and diffusion weighted imaging (DWI)/ADC. The imaging parameters were as follows: T1WI: repetition time (TR)/echo time (TE) = 2,000~2,400/7.6~18.0 ms; T2WI: TR/TE = 5,000~6,000/100~136 ms; FLAIR: TR/TE = 8,400~9,000/87.0~97.0 ms; and DWI/ADC: TR/TE = 4,000~5,000/77.0~85.0 ms, b = 0, and 1,000 s/mm2. Here, ms represents milliseconds and mm millimeters. Slice thickness was 5 mm and slice spacing was 1.5 mm for all the sequences.
Clinical features including sex, age, and vascular risk factors (hypertension, diabetes mellitus, hyperlipidemia, and coronary heart disease) were also recorded.
Lv P., Yang J., Wang J., Guo Y., Tang Q., Magnier B., Lin J, & Zhou J. (2023). Ischemic stroke prediction of patients with carotid atherosclerotic stenosis via multi-modality fused network. Frontiers in Neuroscience, 17, 1118376.
Full text: Click here
Publication 2023
Asthenia Blindness, Monocular Blood Vessel Brain Carotid Stenosis Common Carotid Artery Computed Tomography Angiography Coronary Arteriosclerosis Diabetes Mellitus Diffusion ECHO protocol Face Females High Blood Pressures Hyperlipidemia Institutional Ethics Committees Internal Carotid Artery Stenosis Magnetic Resonance Angiography Males Nervous System Abnormality Nuclear Magnetic Resonance Patients Stroke, Ischemic
2
Thoracic Computed Tomographic Angiography
computed tomographic angiography was performed with a Philips 256i CT scanner (Brilliance iCT, Philips Healthcare, Cleveland, OH), and the patient was in the supine position. Scanning was performed from the thoracic entrance to the costal diaphragm. The contrast agent was injected with a high-pressure syringe at a speed of 4 mL/seconds, dosage of 30 to 50 mL, and nonionic contrast agent iodohydrin. CT scanning was conducted at the end of a single exhalation, with a breath-holding time of 4 to 7 seconds. noncardiac gating and automatic triggering scanning technologies were used. The scanning parameters were a tube current of 200 to 300 mas/ revolution, tube voltage of 120kv, collimation of 128 × 625, pitch of 0.16 to 0.2, rotation time of 270 to 330 ms, matrix of 512 × 512, and display field of 350 mm.
Hu J., Tian X., Liu X., Ma G, & Li C. (2023). Right ventricular area predicts short-term mortality in acute pulmonary embolism based on CT pulmonary angiography: A retrospective study. Medicine, 102(10), e33116.
Publication 2023
CAT SCANNERS X RAY Computed Tomography Angiography Contrast Media Exhaling Neoplasm Metastasis Patients Pressure Ribs Syringes Vaginal Diaphragm
3
Acute Pulmonary Embolism Prognosis Factors
A total of 225 hospitalized patients who underwent CTPA examination between May 2018 and November 2021 in our hospital were diagnosed with acute pulmonary embolism and were followed up for 30 days. Follow up information was collected via phone calls. The inclusion criteria were patients diagnosed with APE according to the 2019 European Heart Association Guidelines for Diagnosis and Treatment of Acute Pulmonary Embolism,[4 (link)] 256-slice spiral CTPA examination, clinical data, and follow-up data. The exclusion criteria were other cardiac diseases that caused cardiac enlargement, including chronic pulmonary heart disease, rheumatic heart disease, congenital heart disease, cardiomyopathy, and poor computed tomographic angiography image quality.
All participants were divided into 2 groups, the death group and the non-death group, according to the prognosis data obtained 30 days after onset.
The Wells score, D-dimer, CK, and CK-MB data were also collected when the patients were diagnosed with APE. The Wells score criteria[3 (link)] were as follows: history of pulmonary embolism or deep venous thrombosis, heart rate ≥ 100 beats/minutes, history of operation or braking in the past 4 weeks, hemoptysis, active stage of malignant tumor, DVT-related symptoms, and low possibility of diagnosis other than pulmonary embolism. Each item is counted at 1 point. The normal D-dimer reference value was 0 to 0.243μg/mL. The blood and myocardial enzymes, including CK-MB, had normal reference values < 24MB.
Hu J., Tian X., Liu X., Ma G, & Li C. (2023). Right ventricular area predicts short-term mortality in acute pulmonary embolism based on CT pulmonary angiography: A retrospective study. Medicine, 102(10), e33116.
Publication 2023
4-((1,4,8,11-tetraazacyclotetradec-1-yl)methyl)benzoic acid BLOOD Cardiomyopathies Computed Tomography Angiography Congenital Heart Defects Cor Pulmonale Diagnosis Enzymes Europeans fibrin fragment D Heart Heart Diseases Hemoptysis Isoenzyme CPK MB Myocardium Patients Prognosis Pulmonary Embolism Rate, Heart Rheumatic Heart Disease Staging, Cancer
4
Defining Obstructive Coronary Artery Disease in ATTR-CM
All patients included underwent review of medical records for evidence of oeCAD by two study investigators (R.H., N.M.F.), including symptom history, cardiovascular risk factors, healthcare encounters such as ambulatory clinic visits, Emergency Department visits and hospitalizations, and cardiac investigation findings such as electrocardiogram (ECG), cardiac biomarker (troponin and N-terminal pro-B-type natriuretic peptide, NTproBNP), ECG stress test, stress imaging, coronary computed tomography angiography (CCTA), invasive coronary angiography, history of acute coronary syndrome (ACS) or myocardial infarction (MI), and/or coronary artery revascularization. The clinical indication for oeCAD evaluation, in addition to the temporal relation with ATTR-CM diagnosis (occurring before, after, or simultaneous with) was also collected.
As patients with ATTR-CM often have clinical characteristics and/or non-invasive investigation result findings that resemble oeCAD (such as chest pain, chronically elevated troponin levels, and anterior Q-waves on ECG), a strict definition of oeCAD was used for this analysis. A diagnosis of CAD required ≥ 1 of the following criteria: (1) prior history of coronary artery revascularization by either percutaneous coronary intervention (PCI) and/or coronary artery bypass grafting (CABG), (2) obstructive epicardial coronary artery stenosis of ≥ 70% by CCTA or invasive coronary angiography, or ≥ 50% of the left main coronary artery [11 (link)]. This strict criteria was selected in order to definitively confirm the presence of obstructive epicardial coronary artery disease lesions in ATTR-CM patients, and to discriminate the presence oeCAD from patients who may have microvascular coronary artery disease or findings on non-invasive evaluation (such as ECG or echocardiography) that are secondary to myocardial amyloid fibril infiltration but resemble oeCAD. Among patients with a prior history of ACS/MI, all had subsequent confirmatory invasive coronary angiography.
Hassan R., Miller R.J., Howlett J.G., White J.A, & Fine N.M. (2023). Prevalence, incidence and clinical outcomes of epicardial coronary artery disease among transthyretin amyloidosis cardiomyopathy patients. BMC Cardiovascular Disorders, 23, 124.
Full text: Click here
Publication 2023
Acute Coronary Syndrome Amyloid Fibrils Artery, Coronary Biological Markers Chest Pain Clinic Visits Computed Tomography Angiography Coronary Angiography Coronary Artery Disease Coronary Stenosis Diagnosis Echocardiography Electrocardiography Exercise Tests Heart Hospitalization Myocardial Infarction Myocardium Patients Percutaneous Coronary Intervention pro-brain natriuretic peptide (1-76) Troponin TTR protein, human
5
Observational Study of Idiopathic Aortic Dissection
The prospective cohort study was reported in line with Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) (4 (link)). The study was approved by the Institutional Review Board (KY-Q-2021-073-01), with informed consent not required due to its observational nature.
All consecutive patients admitted to the Guangdong Provincial People’s Hospital (Guangdong, China) from January 2016 to April 2021 were enrolled and followed up prospectively. Anthropometric, radiologic, laboratory, and operative data were manually accrued from individual electronic medical records and hospital charts. If there were missing values, we would check with the patient or relatives by phone. Computed Tomography Angiography (CTA) was used to confirm IAAD, demonstrating dissected intimal flap and double-lumen aorta below the diaphragm, with or without visible entry tear. Hypertension was diagnosed according to medical history as blood pressure measured at 140/90 mmHg or higher. Diameter was measured perpendicular to the centerline at the different levels in an outer-to-outer manner, and the maximum was noted. The thrombosis status of false lumen was classified as complete thrombosis (CT), partial thrombosis (PT, concurrent presence of both flow and thrombus), and patency (P) proposed by Tsai et al. (5 (link)). Accidental identification of IAAD indicated that the disease was diagnosed by chance such as routinely physical examination or undergoing imaging not specifically for aortic disease. Those patients usually had no symptoms and the aortic dissection was in chronic phase (6 (link)).
There was a lack of recognized protocol for the optimal management of IAAD. Patients were treated either conservatively with best medical therapy (BMT), or aggressively with OS or EVAR, based on attending surgeon’s judgment and patients’ preference. All-cause death was taken as the primary endpoint and surgical intervention for BMT cohort as the secondary endpoint. Patients were followed up either with clinical visits or phone calls.
Wu J., Wu Y., Li F., Zhuang D., Cheng Y., Chen Z., Yang J., Liu J., Li X., Fan R, & Sun T. (2023). Natural history of isolated abdominal aortic dissection: A prospective cohort study. Frontiers in Cardiovascular Medicine, 10, 1002832.
Full text: Click here
Publication 2023
Accidents Aorta Aortic Diseases Blood Pressure Computed Tomography Angiography Dissecting Aneurysms Ethics Committees, Research High Blood Pressures Patients Physical Examination Respiratory Diaphragm Surgeons Surgical Flaps Tears Therapeutics Thrombosis Thrombus Tunica Intima

Top products related to «Computed Tomography Angiography»

1
Somatom definition flash by Siemens
Sourced in Germany, United States, Japan, Netherlands, United Kingdom
The SOMATOM Definition Flash is a computed tomography (CT) scanner developed by Siemens. It is designed to provide high-quality imaging for a wide range of medical applications. The SOMATOM Definition Flash utilizes advanced technology to capture detailed images of the body, enabling medical professionals to make accurate diagnoses and inform treatment decisions.
2
Somatom force by Siemens
Sourced in Germany, United States, Japan
The SOMATOM Force is a high-performance computed tomography (CT) system developed by Siemens. It is designed to deliver fast, precise, and efficient imaging capabilities for a wide range of clinical applications. The SOMATOM Force features advanced technologies that enable high-quality imaging while minimizing radiation exposure.
3
Brilliance ict by Philips
Sourced in United States, Netherlands, Germany, Japan, Israel
The Brilliance iCT is a computed tomography (CT) imaging system developed by Philips. It is designed to capture high-quality, three-dimensional images of the body for medical diagnostic purposes. The Brilliance iCT utilizes advanced imaging technology to provide detailed visualization of anatomical structures, enabling healthcare professionals to make informed decisions about patient care.
4
Somatom definition as by Siemens
Sourced in Germany, United States, Japan, Netherlands, United Kingdom, China
The SOMATOM Definition AS is a computed tomography (CT) imaging system manufactured by Siemens. It is designed to provide high-quality medical imaging for diagnostic purposes. The core function of the SOMATOM Definition AS is to generate detailed cross-sectional images of the human body using X-ray technology.
5
Somatom definition by Siemens
Sourced in Germany, United States, Japan, Netherlands
The Somatom Definition is a computed tomography (CT) scanner developed by Siemens. It is a diagnostic imaging device that uses X-rays to create detailed cross-sectional images of the body.
6
Aquilion one by Toshiba
Sourced in Japan, Germany, United States
The Aquilion ONE is a computed tomography (CT) scanner developed by Toshiba. It is capable of performing whole-body scans in a single rotation, allowing for faster and more comprehensive imaging. The Aquilion ONE utilizes advanced technology to capture high-quality images, but a detailed description of its core function is not available without extrapolation or interpretation.
7
Brilliance 64 by Philips
Sourced in United States, Netherlands, Germany, Japan, United Kingdom
The Philips Brilliance 64 is a computed tomography (CT) imaging system designed for medical diagnostic purposes. It features a 64-slice detector configuration, enabling rapid data acquisition and high-resolution imaging. The Brilliance 64 provides detailed anatomical information to support clinical decision-making for a variety of medical applications.
8
Ultravist 370 by Bayer
Sourced in Germany, United States, Italy, United Kingdom, Switzerland
Ultravist 370 is a non-ionic, water-soluble contrast medium used for radiographic examinations. It contains the active ingredient iopromide and has a concentration of 370 mg iodine per milliliter.
9
Lightspeed vct by GE Healthcare
Sourced in United States, Germany, Japan, United Kingdom, Netherlands
The LightSpeed VCT is a computed tomography (CT) imaging system produced by GE Healthcare. It is designed to provide high-quality, high-speed imaging for a variety of medical applications. The LightSpeed VCT features a multi-slice detector array that enables rapid data acquisition and reconstruction, allowing for efficient patient scanning.
10
Aquilion 64 by Toshiba
Sourced in Japan, Germany, United States
The Aquilion 64 is a computed tomography (CT) scanner manufactured by Toshiba. It is designed to capture high-quality, three-dimensional images of the human body. The Aquilion 64 is capable of producing 64 slices of image data per rotation, allowing for rapid and efficient data acquisition.

More about "Computed Tomography Angiography"

Computed Tomography Angiography (CTA) is a non-invasive, cutting-edge medical imaging technique that utilizes advanced X-ray technology and sophisticated computer algorithms to generate highly detailed, three-dimensional visualizations of the body's intricate network of blood vessels.
This revolutionary diagnostic tool is widely employed in the evaluation and management of cardiovascular conditions, including coronary artery disease, aortic aneurysms, and peripheral vascular disorders.
The CTA procedure involves the injection of a contrast dye into the bloodstream, which enhances the visibility of the blood vessels on the CT scans.
This allows clinicians to obtain high-resolution, comprehensive images that can aid in the early detection, diagnosis, and monitoring of vascular abnormalities.
CTA has become an indispensable tool in modern cardiovascular care, enabling healthcare professionals to develop personalized treatment strategies and improve patient outcomes.
Cutting-edge CTA imaging platforms, such as the SOMATOM Definition Flash, SOMATOM Force, Brilliance iCT, SOMATOM Definition AS, Somatom Definition, Aquilion ONE, Brilliance 64, and LightSpeed VCT, have revolutionized the field of cardiovascular imaging.
These advanced systems leverage state-of-the-art technologies, including Ultravist 370 contrast dye, to deliver exceptionally detailed and accurate visualizations of the cardiovascular system.
Whether you're a medical professional or a researcher, exploring the world of Computed Tomography Angiography (CTA) can open up new possibilities in the diagnosis, treatment, and management of cardiovascular diseases.
Stay ahead of the curve by discovering the latest advancements and optimizing your research protocols with the help of innovative platforms like PubCompare.ai.